European Respiratory Society
@europeanrespsoc.bsky.social
A non-profit organisation dedicated to sharing scientific knowledge, fighting lung disease and promoting lung health. ERS has more than 35,000 members worldwide. ersnet.org
ERR: Several countries have recently updated their recommendations by including PCV20 in vaccination strategies for older adults and individuals at high risk for pneumococcal disease. PCV20 is safe, effective and believed to reduce healthcare costs. https://bit.ly/425aeVL
November 18, 2025 at 5:51 PM
ERR: Several countries have recently updated their recommendations by including PCV20 in vaccination strategies for older adults and individuals at high risk for pneumococcal disease. PCV20 is safe, effective and believed to reduce healthcare costs. https://bit.ly/425aeVL
ERJ Open Res: Novel electrochemical NO measurement during laryngeal mask ventilation showed promising repeatability and precision in screening for PCD in children <5 years. This may help diagnose PCD in young patients and simplify differential diagnostics. https://bit.ly/43kifHf
November 18, 2025 at 4:13 PM
ERJ Open Res: Novel electrochemical NO measurement during laryngeal mask ventilation showed promising repeatability and precision in screening for PCD in children <5 years. This may help diagnose PCD in young patients and simplify differential diagnostics. https://bit.ly/43kifHf
More than 1,400 delegates from 162 Parties have gathered in Geneva this week for #COP11, the world’s main decision-making forum on tobacco control under the WHO Framework Convention on Tobacco Control.
Read the ERS statement to COP11: https://bit.ly/49IHozh
#lunghealth
Read the ERS statement to COP11: https://bit.ly/49IHozh
#lunghealth
November 18, 2025 at 10:16 AM
More than 1,400 delegates from 162 Parties have gathered in Geneva this week for #COP11, the world’s main decision-making forum on tobacco control under the WHO Framework Convention on Tobacco Control.
Read the ERS statement to COP11: https://bit.ly/49IHozh
#lunghealth
Read the ERS statement to COP11: https://bit.ly/49IHozh
#lunghealth
European Respiratory Review: Several gene mutations have been reported to cause early-onset emphysema with known Mendelian traits. Next-generation sequencing offers a promising method to understand early-onset emphysema and COPD pathogenesis. https://bit.ly/4695zEM
November 17, 2025 at 5:13 PM
European Respiratory Review: Several gene mutations have been reported to cause early-onset emphysema with known Mendelian traits. Next-generation sequencing offers a promising method to understand early-onset emphysema and COPD pathogenesis. https://bit.ly/4695zEM
ERJOR: Hospitalisations for bronchiectasis have unique socioeconomic and healthcare utilisation profiles, with worse outcomes than COPD and asthma. Outcomes for bronchiectasis overlap with COPD or asthma were no worse than those for bronchiectasis alone. https://bit.ly/3GVx2zk
November 17, 2025 at 3:45 PM
ERJOR: Hospitalisations for bronchiectasis have unique socioeconomic and healthcare utilisation profiles, with worse outcomes than COPD and asthma. Outcomes for bronchiectasis overlap with COPD or asthma were no worse than those for bronchiectasis alone. https://bit.ly/3GVx2zk
At #COP11, ERS urges governments to take decisive steps to end the tobacco epidemic and the pollution it leaves behind 🚭🌍
Learn more and read the ERS statement to COP11: https://bit.ly/3LJ1X4o
#Tobaccocontrol #Tobaccoendgame @whofctc.bsky.social
Learn more and read the ERS statement to COP11: https://bit.ly/3LJ1X4o
#Tobaccocontrol #Tobaccoendgame @whofctc.bsky.social
November 17, 2025 at 10:14 AM
At #COP11, ERS urges governments to take decisive steps to end the tobacco epidemic and the pollution it leaves behind 🚭🌍
Learn more and read the ERS statement to COP11: https://bit.ly/3LJ1X4o
#Tobaccocontrol #Tobaccoendgame @whofctc.bsky.social
Learn more and read the ERS statement to COP11: https://bit.ly/3LJ1X4o
#Tobaccocontrol #Tobaccoendgame @whofctc.bsky.social
Patients with severe asthma and blood eosinophil counts ≥150–<300 cells/μL showed reduced severe disease exacerbations and maintenance oral corticosteroid use with mepolizumab, whilst improving asthma control and lung function in routine clinical practice https://bit.ly/40dTdHR
November 15, 2025 at 4:08 PM
Patients with severe asthma and blood eosinophil counts ≥150–<300 cells/μL showed reduced severe disease exacerbations and maintenance oral corticosteroid use with mepolizumab, whilst improving asthma control and lung function in routine clinical practice https://bit.ly/40dTdHR
ERJ Open Research: A Chatbot-guided application provided educational content incorporating GINA guidelines and direct contact with pulmonology specialists. Compared with standard therapeutic education, its use was associated with improvements in QoL. https://bit.ly/4fzXWu8
November 15, 2025 at 1:15 PM
ERJ Open Research: A Chatbot-guided application provided educational content incorporating GINA guidelines and direct contact with pulmonology specialists. Compared with standard therapeutic education, its use was associated with improvements in QoL. https://bit.ly/4fzXWu8
ERJ Open Research: Cough-variant asthma exhibits overlapping but distinct airway transcriptomic profiles compared to classic asthma. Two distinct inflammatory endotypes of cough-variant asthma are identified, presenting different clinical outcomes. https://bit.ly/3Zmgjvs
November 14, 2025 at 4:51 PM
ERJ Open Research: Cough-variant asthma exhibits overlapping but distinct airway transcriptomic profiles compared to classic asthma. Two distinct inflammatory endotypes of cough-variant asthma are identified, presenting different clinical outcomes. https://bit.ly/3Zmgjvs
Asthma or allergic asthma in the mother increases the risk of asthma in the child. Higher maternal lung function in pregnancy leads to a lower risk of asthma in the child. https://bit.ly/4cTSy3n
November 14, 2025 at 3:17 PM
Asthma or allergic asthma in the mother increases the risk of asthma in the child. Higher maternal lung function in pregnancy leads to a lower risk of asthma in the child. https://bit.ly/4cTSy3n
European Respiratory Journal: FENO testing at attack can identify the patients on anti-IL5/IL5Rα biologics who have the most lung function and symptom benefits from prednisolone https://bit.ly/3KhMB68
November 14, 2025 at 1:49 PM
European Respiratory Journal: FENO testing at attack can identify the patients on anti-IL5/IL5Rα biologics who have the most lung function and symptom benefits from prednisolone https://bit.ly/3KhMB68
New Interactive Education video available: Early diagnosis of ILD!
Join Prof. Elisabetta Renzoni, Prof. Sara Tomasetti, and Dr Raphael Borie as they use real-world clinical scenarios to discuss critical gaps in knowledge.
Watch now on the ERS Respiratory Channel: https://bit.ly/443ekP3
Join Prof. Elisabetta Renzoni, Prof. Sara Tomasetti, and Dr Raphael Borie as they use real-world clinical scenarios to discuss critical gaps in knowledge.
Watch now on the ERS Respiratory Channel: https://bit.ly/443ekP3
November 14, 2025 at 12:59 PM
New Interactive Education video available: Early diagnosis of ILD!
Join Prof. Elisabetta Renzoni, Prof. Sara Tomasetti, and Dr Raphael Borie as they use real-world clinical scenarios to discuss critical gaps in knowledge.
Watch now on the ERS Respiratory Channel: https://bit.ly/443ekP3
Join Prof. Elisabetta Renzoni, Prof. Sara Tomasetti, and Dr Raphael Borie as they use real-world clinical scenarios to discuss critical gaps in knowledge.
Watch now on the ERS Respiratory Channel: https://bit.ly/443ekP3
ERJ Open Research: The risk of pulmonary embolism was clinically lower in patients with purulent acute exacerbation of COPD (AECOPD) compared to patients with nonpurulent/unknown aetiology AECOPD https://bit.ly/4leYsQt
November 13, 2025 at 6:47 PM
ERJ Open Research: The risk of pulmonary embolism was clinically lower in patients with purulent acute exacerbation of COPD (AECOPD) compared to patients with nonpurulent/unknown aetiology AECOPD https://bit.ly/4leYsQt
ERJ: In this pilot study in 20 adults with cystic fibrosis and iron deficiency, treatment with intravenous iron improved blood haemoglobin concentration and exercise capacity, without any adverse effect on clinical or laboratory markers of infection https://bit.ly/47eQKkR
November 13, 2025 at 5:13 PM
ERJ: In this pilot study in 20 adults with cystic fibrosis and iron deficiency, treatment with intravenous iron improved blood haemoglobin concentration and exercise capacity, without any adverse effect on clinical or laboratory markers of infection https://bit.ly/47eQKkR
European Respiratory Journal: Basophils play crucial roles in the acute respiratory distress syndrome resolution phase by producing IL-4 that act on neutrophils and alleviate acute lung inflammation in model mice https://bit.ly/44SJ3iz
November 13, 2025 at 3:45 PM
European Respiratory Journal: Basophils play crucial roles in the acute respiratory distress syndrome resolution phase by producing IL-4 that act on neutrophils and alleviate acute lung inflammation in model mice https://bit.ly/44SJ3iz
European Respiratory Journal: Immunosuppressive macrophages contribute to the disease progression of LAM https://bit.ly/43YosJa
November 12, 2025 at 5:30 PM
European Respiratory Journal: Immunosuppressive macrophages contribute to the disease progression of LAM https://bit.ly/43YosJa
ERJ Open Research: It seems advisable to systematically detect and correct patient–ventilator interactions in home mechanical ventilated patients https://bit.ly/4hTsyq3
November 12, 2025 at 3:55 PM
ERJ Open Research: It seems advisable to systematically detect and correct patient–ventilator interactions in home mechanical ventilated patients https://bit.ly/4hTsyq3
Learn more about recent scientific developments in pneumonia this #WorldPneumoniaDay with our ERS Publications collection 🦠
Access information on community-acquired pneumonia, drug-resistance, and more: https://bit.ly/49wuAvN
Access information on community-acquired pneumonia, drug-resistance, and more: https://bit.ly/49wuAvN
November 12, 2025 at 1:14 PM
Learn more about recent scientific developments in pneumonia this #WorldPneumoniaDay with our ERS Publications collection 🦠
Access information on community-acquired pneumonia, drug-resistance, and more: https://bit.ly/49wuAvN
Access information on community-acquired pneumonia, drug-resistance, and more: https://bit.ly/49wuAvN
Defend and trust in science. Protect public health.
That is our message to European Union leaders. Watch as Joanna Chorostowska-Wynimko, ERS President, explains 💬
That is our message to European Union leaders. Watch as Joanna Chorostowska-Wynimko, ERS President, explains 💬
November 12, 2025 at 12:07 PM
Defend and trust in science. Protect public health.
That is our message to European Union leaders. Watch as Joanna Chorostowska-Wynimko, ERS President, explains 💬
That is our message to European Union leaders. Watch as Joanna Chorostowska-Wynimko, ERS President, explains 💬
Eur Respir J: The impairment of IgA-related mucosal immunity after lung transplantation occurs early in the development of bronchiolitis obliterans syndrome (BOS), preceding clinical diagnosis. This suggests its potential as a predictor for BOS onset. https://bit.ly/3RVMmyp
November 11, 2025 at 4:14 PM
Eur Respir J: The impairment of IgA-related mucosal immunity after lung transplantation occurs early in the development of bronchiolitis obliterans syndrome (BOS), preceding clinical diagnosis. This suggests its potential as a predictor for BOS onset. https://bit.ly/3RVMmyp
ERJ Open Research: ETI therapy in patients with NCFB and an amenable CFTR mutation led to a significant improvement in pulmonary function, clinical status and daily symptoms, suggesting ETI may prove beneficial as an adjuvant therapy for NCFB https://bit.ly/3DVXiIQ
November 11, 2025 at 2:47 PM
ERJ Open Research: ETI therapy in patients with NCFB and an amenable CFTR mutation led to a significant improvement in pulmonary function, clinical status and daily symptoms, suggesting ETI may prove beneficial as an adjuvant therapy for NCFB https://bit.ly/3DVXiIQ
📖 The forthcoming ERS Monograph on “Chronic Cough” is now available to pre-order. The book will cover pathophysiology, assessment, management, treatable traits & future directions.
Pre-order before 16 Nov & receive a €10 discount: https://bit.ly/43o6YVY
Pre-order before 16 Nov & receive a €10 discount: https://bit.ly/43o6YVY
November 10, 2025 at 10:52 AM
📖 The forthcoming ERS Monograph on “Chronic Cough” is now available to pre-order. The book will cover pathophysiology, assessment, management, treatable traits & future directions.
Pre-order before 16 Nov & receive a €10 discount: https://bit.ly/43o6YVY
Pre-order before 16 Nov & receive a €10 discount: https://bit.ly/43o6YVY
ERJ Open Research: Patients who experienced CV events after COPD exacerbations received more intensive COPD treatment and had more HCRU compared with patients whose CV events occurred without COPD exacerbations in the prior 12 months https://bit.ly/4iuPxaW
November 8, 2025 at 1:15 PM
ERJ Open Research: Patients who experienced CV events after COPD exacerbations received more intensive COPD treatment and had more HCRU compared with patients whose CV events occurred without COPD exacerbations in the prior 12 months https://bit.ly/4iuPxaW
🎙️ ERJ Podcast: Listen as Deputy Chief Editor Don Sin interviews Section Editor Isabella Annesi-Maesano about natural disasters and respiratory health, as discussed in Isabella’s article in the most recent edition of the ERJ.
Listen: https://channel.ersnet.org/channel-86-erj-podcast?contId=114954
Listen: https://channel.ersnet.org/channel-86-erj-podcast?contId=114954
November 7, 2025 at 4:07 PM
🎙️ ERJ Podcast: Listen as Deputy Chief Editor Don Sin interviews Section Editor Isabella Annesi-Maesano about natural disasters and respiratory health, as discussed in Isabella’s article in the most recent edition of the ERJ.
Listen: https://channel.ersnet.org/channel-86-erj-podcast?contId=114954
Listen: https://channel.ersnet.org/channel-86-erj-podcast?contId=114954
ERJOR: Disease-modifying treatments in COPD are currently lacking. A novel platform for imaging inflammatory cytokine activity in airway disease may provide a new precision medicine approach to determine the most appropriate treatment for an individual. https://bit.ly/42BrJfH
November 7, 2025 at 3:13 PM
ERJOR: Disease-modifying treatments in COPD are currently lacking. A novel platform for imaging inflammatory cytokine activity in airway disease may provide a new precision medicine approach to determine the most appropriate treatment for an individual. https://bit.ly/42BrJfH